Related Experiment Video
Updated: Jan 27, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Risk of Ischemic Stroke and Peripheral Arterial Disease in Heterozygous Familial Hypercholesterolemia: A
Leo E Akioyamen1,2, Jack V Tu1,2,3, Jacques Genest4,5
11 Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Insights
Heterozygous familial hypercholesterolemia (HeFH) significantly increases peripheral arterial disease (PAD) risk. While HeFH may not raise ischemic stroke risk, elevated LDL-C levels in HeFH patients show a modest association with stroke.
Area of Science:
- Cardiovascular Science
- Genetics
- Epidemiology
Background:
- Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder causing lifelong high LDL-C and coronary heart disease.
- The association between HeFH and peripheral arterial disease (PAD) or ischemic stroke remains unclear.
Purpose of the Study:
- To investigate the relationship between HeFH and the risk of PAD and ischemic stroke.
- To conduct a systematic review and meta-analysis of existing studies.
Main Methods:
- Searched major databases (MEDLINE, EMBASE, etc.) for relevant English-language studies.
- Pooled maximally adjusted risk estimates using random- and fixed-effects meta-analysis.
- Included 6 studies with 183,388 participants.
Main Results:
- HeFH was linked to a higher risk of PAD (OR: 3.59).
- This association persisted in sensitivity analyses of genetically defined HeFH (OR: 2.96).
- Genetic HeFH showed no increased ischemic stroke risk (OR: 0.76), but LDL-C >4.9 mmol/L was associated with stroke risk (OR: 1.42).
Conclusions:
- Clinical and genetic diagnoses of HeFH are associated with an increased risk of PAD.
- Genetically confirmed HeFH may not increase ischemic stroke risk.
- A modest association might exist between LDL-C levels and ischemic stroke risk in HeFH patients.
Abstract:
Heterozygous familial hypercholesterolemia (HeFH) is a common genetic disorder predisposing affected individuals to lifelong low-density lipoprotein cholesterol (LDL-C) elevation and coronary heart disease. However, whether HeFH increases the risk of peripheral arterial disease (PAD) and ischemic stroke is undetermined. We examined associations between HeFH and these outcomes in a comprehensive systematic review and meta-analysis. We searched MEDLINE, EMBASE, Global Health, the Cochrane Library, and PubMed (for ahead-of-print publications) for relevant English-language studies. Maximally adjusted risk estimates were pooled under random- and fixed-effects meta-analysis to derive odds ratios (ORs) and 95% confidence intervals (CIs). We included 6 studies representing 183 388 participants. Heterozygnous familial hypercholesterolemia was associated with a higher risk of PAD (OR: 3.59 [95% CI: 1.30-9.89]). This trend was nonsignificantly preserved (OR: 2.96 [95% CI: 0.68-12.88]) in sensitivity analyses of genetically defined HeFH. Genetic HeFH was not associated with increased ischemic stroke risk (OR: 0.76 [95% CI: 0.37-1.58]) although possessing an LDL-C >4.9 mmol/L (190 mg/dL) was (OR: 1.42 [95% CI: 1.06-1.89]). We found clinical and genetic diagnoses of HeFH to be associated with increased PAD risk. Genetically confirmed HeFH may not confer an increased risk of ischemic stroke. Modest associations may exist between LDL-C and ischemic stroke risk in HeFH.
Related Concept Videos
Peripheral Artery Disease I: Introduction
Peripheral Artery Disease IV: Nursing Management
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Protein Families

